[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"molecular-residual-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:molecular-residual-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100652612","research-on-colorectal-cancer-recurrence-monitoring-and-individualized-treatment-based-on-mrd-100652612",false,"NCT07775950","Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD","Inclusion Criteria:\n\n1. Voluntary participation in the study and provision of written informed consent.\n2. Age ≥18 years at the time of signing informed consent.\n3. Histologically confirmed colorectal adenocarcinoma with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) status.\n4. Clinically confirmed stage IV disease.\n5. No prior immunotherapy for the current colorectal cancer.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n7. Availability of adequate pretreatment tumor tissue and peripheral blood samples for whole-exome sequencing (WES) and personalized circulating tumor DNA (ctDNA)\u002FMRD analysis.\n8. Life expectancy \\>12 months.\n9. Willing and able to comply with the study procedures and scheduled follow-up.\n\nExclusion Criteria:\n\n1. Presence of another malignancy.\n2. Prior immunotherapy for the current stage IV colorectal cancer.\n3. Organ transplantation within 3 months before enrollment.\n4. History of blood transfusion within 3 months before enrollment.\n5. Active, known, or suspected autoimmune disease, or evidence of active or chronic infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus (HIV).\n6. Pregnancy or breastfeeding.\n7. Presence of a serious concurrent disease that, in the investigator's judgment, may substantially affect life expectancy or study participation.\n8. Failure to provide written informed consent.\n9. Any other condition that, in the investigator's judgment, makes the participant unsuitable for enrollment.",true,"ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate whether plasma molecular residual disease (MRD), assessed using circulating tumor DNA (ctDNA), can help optimize the duration of immunotherapy in patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer.\n\nPatients with MSI-H\u002FdMMR metastatic colorectal cancer can achieve durable responses to immune checkpoint inhibitors, but the optimal duration of treatment remains uncertain. Prolonged immunotherapy may increase treatment burden and the risk of immune-related adverse events. ctDNA-based MRD testing may provide a sensitive method for detecting residual tumor burden and identifying patients who may be able to safely stop treatment.\n\nIn this study, patients receiving immunotherapy will undergo serial plasma MRD testing. After completing 1 year of immunotherapy, patients with two consecutive negative MRD results will be randomly assigned to either continue immunotherapy or stop treatment and enter observation. Patients will then be followed every 3 months for 2 years with MRD testing and routine clinical assessments, including imaging and laboratory examinations.\n\nThe study will compare clinical outcomes between the two groups and evaluate whether serial plasma MRD monitoring can support a more individualized approach to the duration of immunotherapy in MSI-H\u002FdMMR metastatic colorectal cancer.",[26,27],"Colorectal Cancer (MSI-H)","Molecular Residual Disease","RECRUITING","2026-08-16",{"date":31,"type":32},"2026-08-20","ACTUAL",{"date":34,"type":32},"2026-06-23",{"date":36,"type":20},"2034-12-30",{"name":38,"class":39},"Sun Yat-sen University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100646501","unified-network-for-integrated-fluid-collection-at-yale-100646501","NCT07689864","Unified Network for Integrated Fluid Collection at Yale","UNIFY","Inclusion Criteria:\n\n* Histological or radiological evidence of a suspected or confirmed solid tumor or hematologic malignancy, OR an individual identified as high-risk for cancer (based on identified germline aberration in a cancer predisposition gene, hormonal or medical risk factors, and\u002For significant family history of malignancy).\n* Willing and able to provide informed consent and HIPAA authorization for participation in UNIFY.\n* If being co-consented for a separate primary research study, the participant must also fulfill the eligibility criteria for that primary research study. Where there is a discrepancy in eligibility criteria between UNIFY and the primary research study, the primary research study's criteria take precedence.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Any medical contraindication to peripheral venipuncture as judged by the treating physician or research team (e.g., severe coagulopathy or other contraindication to additional research blood draw).",{"count":49,"type":20},2500,"OBSERVATIONAL","UNIFY is a Yale-wide liquid biopsy master repository that prospectively collects Streck-tube blood, dried blood spots (and optional archival tissue) from Yale Cancer Center patients across all tumor types for current and future research.",[27,53],"Cancer",[55],"Liquid Biopsy","NOT_YET_RECRUITING","2026-07-01",{"date":59,"type":32},"2026-07-08",{"date":61,"type":20},"2026-08",{"date":63,"type":20},"2031-08",{"name":65,"class":39},"Yale University"]